Key result
Digoxin use in atrial fibrillation was associated with higher unadjusted mortality (51% vs 31%, p<0.001), but had a neutral effect on mortality and major cardiovascular events after adjustment.
Why the study?
Does digoxin affect mortality and major cardiovascular events in patients with atrial fibrillation?
Population
2,824 patients with atrial fibrillation (AF)
Comparison
Digoxin vs No digoxin
Design
Cohort
Follow-up
mean 4.6 years
Authors
Loading...
Should not yet change digoxin prescribing in AF; leaves open need for RCTs to confirm neutral adjusted effects.
Cohort (n=2,824)
Does digoxin affect mortality and major cardiovascular events in patients with atrial fibrillation?
Absolute Event Rate: 51% vs 31%
p-value: p=<0.001
In patients with atrial fibrillation, digoxin use is primarily driven by older age and frailty, but after adjusting for these confounders, it has a neutral effect on mortality and major cardiovascular events.
Friberg et al. (2009) conducted a cohort in Atrial fibrillation (n=2,824). Digoxin vs. No digoxin was evaluated on All-cause mortality (unadjusted) (p=<0.001). Digoxin use in atrial fibrillation was associated with higher unadjusted mortality (51% vs 31%, p<0.001), but had a neutral effect on mortality and major cardiovascular events after adjustment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: